Hepatocyte-like cells derived from induced pluripotent stem cells: A versatile tool to understand lipid disorders

Lars E. Larsen; Mikhaila A. Smith; Deepti Abbey; Amber Korn; Laurens F. Reeskamp; Nicholas J. Hand; Adriaan G. Holleboom

doi:https://doi.org/10.1016/j.atherosclerosis.2020.03.014

Hepatocyte-like cells derived from induced pluripotent stem cells: A versatile tool to understand lipid disorders

Lars E. Larsen, Mikhaila A. Smith, Deepti Abbey, Amber Korn, Laurens F. Reeskamp, Nicholas J. Hand, Adriaan G. Holleboom

Research output: Contribution to journal › Review article › Academic › peer-review

7 Citations (Scopus)

Abstract

Dyslipidemias are strongly linked to the development of atherosclerotic cardiovascular disease. Most dyslipidemias find their origin in the liver. In recent years, the differentiation of induced pluripotent stem cells (iPSCs) into hepatocyte-like cells has provided a versatile platform for the functional study of various dyslipidemias, both rare genetic dyslipidemia as well as common lipid disorders associated with insulin resistance or non-alcoholic fatty liver disease. In addition, iPSC-derived hepatocytes can serve as a cell model for developing novel lipid lowering therapies and have the potential of regenerative medicine. This review provides an overview of these developments.

Original language	English
Pages (from-to)	8-14
Number of pages	7
Journal	Atherosclerosis
Volume	303
DOIs	https://doi.org/10.1016/j.atherosclerosis.2020.03.014
Publication status	Published - 1 Jun 2020

Keywords

Drug testing
Dyslipidemias
Liver organoids
Non-alcohol fatty liver disease
Regenerative medicine

Access to Document

https://doi.org/10.1016/j.atherosclerosis.2020.03.014

Cite this

@article{00b8aee2ebfa48e39e15665adda81461,

title = "Hepatocyte-like cells derived from induced pluripotent stem cells: A versatile tool to understand lipid disorders",

abstract = "Dyslipidemias are strongly linked to the development of atherosclerotic cardiovascular disease. Most dyslipidemias find their origin in the liver. In recent years, the differentiation of induced pluripotent stem cells (iPSCs) into hepatocyte-like cells has provided a versatile platform for the functional study of various dyslipidemias, both rare genetic dyslipidemia as well as common lipid disorders associated with insulin resistance or non-alcoholic fatty liver disease. In addition, iPSC-derived hepatocytes can serve as a cell model for developing novel lipid lowering therapies and have the potential of regenerative medicine. This review provides an overview of these developments.",

keywords = "Drug testing, Dyslipidemias, Liver organoids, Non-alcohol fatty liver disease, Regenerative medicine",

author = "Larsen, {Lars E.} and Smith, {Mikhaila A.} and Deepti Abbey and Amber Korn and Reeskamp, {Laurens F.} and Hand, {Nicholas J.} and Holleboom, {Adriaan G.}",

year = "2020",

month = jun,

day = "1",

doi = "https://doi.org/10.1016/j.atherosclerosis.2020.03.014",

language = "English",

volume = "303",

pages = "8--14",

journal = "Atherosclerosis",

issn = "0021-9150",

publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Hepatocyte-like cells derived from induced pluripotent stem cells: A versatile tool to understand lipid disorders

AU - Larsen, Lars E.

AU - Smith, Mikhaila A.

AU - Abbey, Deepti

AU - Korn, Amber

AU - Reeskamp, Laurens F.

AU - Hand, Nicholas J.

AU - Holleboom, Adriaan G.

PY - 2020/6/1

Y1 - 2020/6/1

N2 - Dyslipidemias are strongly linked to the development of atherosclerotic cardiovascular disease. Most dyslipidemias find their origin in the liver. In recent years, the differentiation of induced pluripotent stem cells (iPSCs) into hepatocyte-like cells has provided a versatile platform for the functional study of various dyslipidemias, both rare genetic dyslipidemia as well as common lipid disorders associated with insulin resistance or non-alcoholic fatty liver disease. In addition, iPSC-derived hepatocytes can serve as a cell model for developing novel lipid lowering therapies and have the potential of regenerative medicine. This review provides an overview of these developments.

AB - Dyslipidemias are strongly linked to the development of atherosclerotic cardiovascular disease. Most dyslipidemias find their origin in the liver. In recent years, the differentiation of induced pluripotent stem cells (iPSCs) into hepatocyte-like cells has provided a versatile platform for the functional study of various dyslipidemias, both rare genetic dyslipidemia as well as common lipid disorders associated with insulin resistance or non-alcoholic fatty liver disease. In addition, iPSC-derived hepatocytes can serve as a cell model for developing novel lipid lowering therapies and have the potential of regenerative medicine. This review provides an overview of these developments.

KW - Drug testing

KW - Dyslipidemias

KW - Liver organoids

KW - Non-alcohol fatty liver disease

KW - Regenerative medicine

UR - http://www.scopus.com/inward/record.url?scp=85085023968&partnerID=8YFLogxK

U2 - https://doi.org/10.1016/j.atherosclerosis.2020.03.014

DO - https://doi.org/10.1016/j.atherosclerosis.2020.03.014

M3 - Review article

C2 - 32460140

SN - 0021-9150

VL - 303

SP - 8

EP - 14

JO - Atherosclerosis

JF - Atherosclerosis

ER -

Hepatocyte-like cells derived from induced pluripotent stem cells: A versatile tool to understand lipid disorders

Abstract

Keywords

Access to Document

Other files and links

Cite this